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The costs and benefits of hospice and palliative care have recently received
attention for many compelling reasons. First, the cost of medical care over a
lifetime is largely expended near the end-of-life [1]. The impending demographic
bulge of aging baby boomers will only heighten concerns about costs. Second,
hospice and palliative care have been offered as potential vehicles for reducing
late-in-life spending [2]. Third, palliative care has gained legitimacy as a distinct
medical specialty, having as it does a characteristic philosophy, specialized skill
sets, and specific service delivery needs [3]. This philosophy of care is consis-
tent with and, to some degree, builds on the philosophy of care that geriatrics
also promotes (see the article by Cox Hayley and Sachs elsewhere in this issue
for more information).
In this article, currently accepted standards for cost-benefit analysis of health
care interventions are outlined, and a framework to evaluate palliative care
within these standards is provided. Recent publications on the economic
implications of palliative care are reviewed, which are only the ‘‘tip of the
iceberg’’ of the potential costs and benefits. Using this framework, the authors
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offer guidelines for performing comprehensive cost-benefit analyses of palliative
care and conclude that many of the issues beneath the surface may be substantial
and deserving of closer scrutiny. Methods for gathering relevant cost-benefit
information are detailed, along with potential obstacles to implementation. This
approach is applicable to palliative care in general, including palliative care
for elders.
The gold standard for cost-benefit research
The United States Panel on Cost-Effectiveness convened in the mid-1990s to
establish guidelines for health care cost-benefit and cost-effectiveness research
[4]. The panel concluded that cost-benefit analyses of health care interventions
should consider medical and nonmedical costs and benefits, and many economic
analyses of health care interventions follow these guidelines [5–8]. According to
the guidelines, a comprehensive study should measure the following elements:
1. Changes in use of health care resources. Health care resources include
personnel, materials, and equipment used during the course of treatment.
These expenditures may be offset by reductions in spending for other
medical care services. For example, if hospice use is associated with a
decline in hospitalization, the savings from the latter should be deducted
from the cost of the former. Researchers may apply standard accounting
techniques to measure these resource costs. However, there are consid-
erable issues associated with the allocation of overhead for health care
providers, and research and development costs for suppliers of drugs,
devices, and diagnostic technologies [9]. It may be difficult for researchers
to resolve these issues with available data.
2. Changes in the use of non–health care resources. Health care is time-
consuming. The cost of the time of professional health care providers is
accounted for in the costs of health care resources. Others also invest time
in the medical process. Patients spend time undergoing treatment and
family members divert time from other activities. This detracts from work-
place productivity and leisure. For patients and family members, it is cus-
tomary to value time at the individual’s hourly wage because economic
theory suggests the hourly wage corresponds to marginal workplace
productivity and the marginal value of leisure time. The value of time for
individuals who are not in the labor force, especially retirees, is harder to
pin down. It may be convenient to ignore the benefits of their leisure time.
Nonetheless, ignoring this value would bias cost-benefit estimates in favor
of time-consuming interventions (eg, interventions that require consider-
able travel time or lengthy therapeutic treatments.) Other non–health care
resources may include child care costs for parents who must tend to an
elderly relative and the costs of renovating or remodeling a home to
accommodate the care of a patient with special needs.
boni-saenz et al148
3. Quality and quantity of life. The ultimate goal of most health care in-
terventions is to improve the quality and quantity of life. Quantity can be
measured in various ways, such as life expectancy and infant mortality.
Cost-effectiveness studies increasingly use quality-adjusted life years
(QALY) to account simultaneously for quantity and quality.
There is an imperfect overlap between what is measured in QALY scores and
what is measured under the category ‘‘non–health care resources.’’ For example,
an improvement in health that enables one to work may receive a high QALY
score, precisely because of the ability to work. This creates the potential for
double counting in any study that directly measures non–health care resources
and QALY improvements. This remains an unresolved issue in the broader
literature on cost-effectiveness analysis, but may be especially important in pal-
liative care, where patients may experience large, temporary changes in quality
of life and workplace productivity.
Quality measures need not be restricted to the patient. Interventions may affect
the quality of life of family members as well, independent of the effects on time
and productivity. The panel’s recommendations stress the importance of mea-
suring the full costs and benefits that accrue to society.
Cost-benefit analysis and palliative care
Palliative care impacts patients, caregivers, family members, and the com-
munity in varied ways. Understanding these differences serves as a foundation
for the cost-benefit analysis methodology.
The World Health Organization defines palliative care as ‘‘an approach that
improves the quality of life of patients and their families facing the problem
associated with life-threatening illness, through the prevention and relief of
suffering by means of early identification and impeccable assessment and treat-
ment of pain and other problems, physical, psychosocial and spiritual.’’ Palliative
care also ‘‘offers a support system to help patients live as actively as possible
until death,’’ enhances and prolongs their life, and can aid in family coping [10].
Table 1
A classification of palliative care costs and benefits
Category Potential costs and benefits
Patient medical Improve quality and quantity of life for the patient
Costs of medical care services
Patient nonmedical Changes in workplace productivity of the patient
Accommodations by employers
Family medical Changes in quality of life of family members
Changes in health care use of family members (eg, mental
health expenditures)
Family nonmedical Changes in workplace productivity and school performance of
family members
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This definition identifies many potential costs and benefits of palliative care
that are consistent with the United States Panel of Cost-Effectiveness guidelines.
Table 1 offers a framework for categorizing these costs and benefits in a manner
that is consistent with the guidelines while capturing the essence of the goals of
palliative care. This table distinguishes between patient costs and benefits and
the costs and benefits that accrue to the family. Family is used broadly here to
represent those close to or providing informal care to the patient. Potential costs
and benefits to a broader unit of the community are discussed later in this article.
Medical costs and benefits associated with delivery of health care services and
health outcomes are distinguished from nonmedical costs and benefits associated
primarily with workplace productivity.
To give an idea of how these costs and benefits can manifest themselves in a
real end-of-life situation, consider the case of a woman who had a 2-year
trajectory with adenocarcinoma of unknown origin whose treatment integrated
curative therapy with palliative care [11]. The integrated team of caregivers
allowed for support in the workplace and home, enabling the woman to stay in
the workplace until 2 months before her death (effects: patient nonmedical and
possibly patient medical). Care continued through to the completion of 1 year of
bereavement care for her husband (effect: family medical). This patient’s husband
took some time off work but maintained his job and continued to work after his
wife’s death (effect: family nonmedical). Her children experienced a normal
bereavement and did not suffer declines in workplace or schoolwork quality. This
is probably not an isolated case, as research suggests that palliative care may help
families adjust to the death of a loved one [12]. As a result, families may remain
effective in essential roles in the household and in the workforce (effects: family
medical and family nonmedical).
What has been measured and what remains to be measured
Several studies have examined the effects of palliative care on patient medical
costs. Two recent studies reached similar conclusions. As one report stated,
‘‘There are few solid data that show hospice reduces costs’’ [13,14]. A review of
earlier studies identified three randomized trials of hospice and advanced
directives and also found no demonstrated reductions in medical costs [15].
Based on the latter review of the literature, the authors question congressional
funding of hospice care and conclude, ‘‘We should await further study before
cashing the check.’’ The most recent studies suggest that palliative care may
reduce hospitalizations and intrusive interventions, although these studies do not
directly measure costs [16,17]. No known studies assess the impact of palliative
care on medical costs specifically for elders. Differences in medical need and
symptom prevalence suggest that the calculus may be different.
In focusing on patient medical costs, the research literature to date has ignored
the other important elements of cost-benefit analysis identified by the United
States Panel on Cost-Effectiveness. As a result, claims that we should not ‘‘cash
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the check’’ may be premature. The failure to fully consider all costs and benefits
of palliative care would be acceptable if medical costs dominated all other effects.
Given that palliative care appears to have roughly zero net effect on patient
medical costs, it is imperative to measure other effects. If these nonmedical and
family effects are amplified by the demographic bulge of elders, this will be of
importance in the coming decades; the final conclusion about the cost-benefit
ratio of palliative care depends on it.
The importance of measuring everything
Current studies of palliative care fall short of the goal of measuring all relevant
costs and benefits and instead focus on patient medical costs. This would be
acceptable if two conditions were met: (a) patient medical costs were measured
accurately and (b) the unmeasured components were expected to be of trivial
importance. Unfortunately, one or both conditions are unlikely to be met.
Measuring patient medical costs and benefits
To date, the research literature on palliative care has focused largely on patient
medical costs. Typical methods examine gross charges or, at best, apply ‘‘cost-to-
charge’’ ratios to estimate costs. It is a gross error to use charges to measure costs.
Because of various idiosyncrasies in health care reimbursements, charges often
bear little relation to costs. In hospitals, charges may exceed costs by a factor of
2 or more. By the same token, actual reimbursements are, at best, a good ap-
proximation to costs.
A common approach for measuring costs is to begin with charges and then
apply a cost-to-charge ratio, such as that found in Medicare cost reports. This is
problematic as well because the computation of cost-to-charge ratios is highly
sensitive to the methods chosen for allocating overhead. This is, unfortunately,
common in the medical cost-benefit literature and is not easily addressed. For
example, a study of care for ventilator-assisted children found that the resulting
bias could be substantial, exceeding $10,000 per patient, because the hospital-
ized children received minimal medical attention despite that they were housed
in seemingly high-cost intensive care units [18]. Studies of palliative care should
consider whether hospitalized end-of-life patients receive a level of care that is
commensurate with the allocation of costs.
Studies show that palliative care can improve the quality of life for patients,
but these results have not been integrated into cost-benefit studies. Quantifying
the benefits in dollar terms is a challenge. Currently, the most popular approach
for quantifying the value of life uses tools such as the quality-adjusted life
year. Combining quantity and quality of life, QALYs are built using life expec-
tancy estimates and health-related quality of life weights that are associated with
particular health states. Descriptive health status measures, such as the Quality of
Well-Being scale [19], the EQ-5D [20], and Health Utilities Index [21] are used
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to elicit these values from a given population. Individuals rank symptoms such
as physical function, social function, emotional well-being, and pain. In all
such scales, the ultimate product is a range of health utilities from 0 (death)
to 1 (full health). These health utilities are then multiplied by an appropriate
life expectancy to arrive at many QALYs. Different interventions will ideally
increase either the quantity or quality of life, thus increasing the number of
QALYs gained.
There are four key elements to QALYs that take on challenging new di-
mensions when used to quantify the health benefits of palliative care. The first
is to establish what to measure. Health is a multidimensional concept and the
dimensions of interest are different for the end-of-life. Qualitative research into
patients’ experiences at the end-of-life indicates that other domains of health-
related quality of life, such as the spiritual and familial, become important or even
prominent [22,23]. The results of a recently published survey indicate nearly 40%
of respondents stated that ‘‘achieving a sense of control’’ and ‘‘strengthening
relationships with loved ones’’ were important domains of end-of-life care [24].
Evaluating how to construct or adapt current quality of life measures so that
they will be relevant to the end-of-life and also usable to derive health utilities
is necessary.
The second challenge revives the traditional debate over whose health state
preferences are the proper ones to use in QALYanalysis. The United States Panel
on Cost-Effectiveness has determined that population ratings of health states
should be used to obtain health utilities. However, the preferences of palliative
care patients may not coincide with the preferences of specific patient groups or
the population as a whole. QALYs were developed with the idea that a patient’s
goal is the improvement of their health state. Though short-term improvements in
health are an important goal of palliative care, long-term improvements are, by
definition, unattainable. Traditionally, the population as a whole places lower
weights on the health states of patients than do patients themselves for numerous
potential reasons [25,26]. However, querying end-of-life patients on their pref-
erences would present many challenges, including nonresponse and attrition
biases and the need for proxy respondents.
A third challenge is to establish how to measure quality of life in a way that
accounts for the duration of the condition and the ultimate outcome. It is not
sufficient to ask individuals to place a score on a given condition because it
must be understood that the condition will only last 6 months, and the ultimate
outcome of the condition is death. In the aforementioned study, over 60% of
respondents stated that ‘‘avoiding inappropriate prolongation of dying’’ was an
important aspect of end-of-life care. Realistic measurement scales and techniques
for palliative care must reflect the reality that many patients believe prolonging
life is undesirable.
The final challenge is to place an acceptable dollar value on QALYs. Though
these scales were developed for cost-effectiveness analysis (ie, to provide a
uniform metric with which to evaluate the differential costs of achieving a quality
adjusted year of life), they are not sufficient for cost-benefit analysis [27]. The
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latter requires putting a dollar value on a QALY. Research from the willingness-
to-pay literature shows wide variation in the value placed on a QALY, most likely
due to the various methods one can employ to arrive at a figure [28]. The most
popular approach is to use economic evaluations, such as those described by
Viscusi and Aldy, who place a dollar value of a QALY at about $100,000 to
$200,000 [29]. This approach is not universally accepted and many government
agencies, including those in Australia, Canada, and the United Kingdom, rou-
tinely place a lower dollar value on QALYs when evaluating new technolo-
gies for government reimbursement [30].
To see how sensitive cost-benefit analyses may be to the dollar value placed
on a QALY, consider the following example. One study reports that a patient
whose condition was ‘‘in hospital; limited walking; back pain; needs help for
self-care; loss of consciousness’’ would receive a QALY score of .30 [31]. This
valuation excludes domains of relevance to end-of-life patients, so it is likely
that researchers will have to construct well-being scores de novo. Even so, it is
possible to conjecture about the potential magnitude of quality-of-life effects.
Suppose that the aforementioned patient received palliative care and ex-
perienced a QALY gain from .30 to .40 due to an increased sense of coming to
peace with death, facilitated by palliative care personnel. If this gain lasted for the
final 6 months of this patient’s life, and a conservative estimate of the dollar value
of a QALYof $50,000 is used, there is an implied benefit of $2500. This does not
mean that palliative care would generate benefits of such a magnitude, but merely
points out that, given the substantial dollar value placed on QALYs, even modest
changes in QALY scores can have a considerable impact on benefits.
Patient nonmedical costs and benefits
End-of-life patients incur many nonmedical costs, including costs for
transportation, homemaking, and personal care [32]. End-of-life patients also
lose time from work, although this cost is not well documented. The impact of
palliative care on these nonmedical costs can be great. If the overall cost-benefit
literature is a guide, the effect of palliative care on workplace productivity alone
may be great enough to justify the effort to document these effects. The National
Institutes of Health report that the costs associated with workplace productivity
losses exceed the direct costs of medical care for many diseases, including Alz-
heimer’s disease, cancer, and Parkinson’s disease [33].
If initiated early in the disease, individuals who receive palliative care may
experience declines in productivity because they take time off from work to visit
providers. As the disease progresses, however, palliative care may enable workers
to remain on the job longer. Careful studies should document the net effect of
palliative care on time in the workplace, valuing changes in workplace pro-
ductivity at market wages. Because elders in the workforce will be an important
component of economic viability during the era of aging baby boomers, specific
attention to these effects for elders is also needed. Because palliative care treat-
ment has the potential to shorten or extend workplace productivity by weeks or
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months, the dollar value of the effect will likely be measured, at a minimum, in
the thousands of dollars.
Palliative care will also affect the time available to patients who are not in the
labor force. The issues associated with valuing this time for cost-benefit analysis
can be complex and are beyond the scope of this essay. The value of leisure time
is implicitly accounted for in QALY scores and should not be double-counted.
Employers of patients who receive palliative care may need to make special
workplace accommodations, perhaps to stay in compliance with the Americans
with Disabilities Act. Examples may range from reconfiguring an employee’s
workspace to purchasing specialized machines and materials. Though the cost of
many accommodations is negligible or low, they can at times be expensive and
must be included in the analysis [34].
Family medical costs and benefits
Illness and death affect not only the patient but family members who endure
the caregiving and bereavement processes. In the same way, palliative care is a
health intervention that will affect the family as well as the patient. The effects of
illness and death care on paid, formal caregivers are not discussed here as these
costs are presumably factored into their wages and need not be considered
separately. The health effects on informal caregivers are, however, of concern to
palliative care researchers. In several studies, caregiver burden has been as-
sociated with various negative health effects [35,36]. Caregiving has also been
cited as an independent risk factor for mortality [37]. The literature on caregiving
burden has tended to oversample those caregivers who are most at risk for
developing health problems, such as dementia caregivers. Indeed, a recent study
indicated that noncaregivers who reported severe parental disability were sig-
nificantly more likely to experience symptoms of depression, and that caregivers
were not found to experience depressive symptoms [38]. A recent meta-analysis,
however, showed that negative health effects, such as increased stress, de-
pression, subjective well-being, and physical health, still exist for more rep-
resentative samples of caregivers [39].
The palliative care paradigm, with its potential to improve the quality of death
for the patient and family, may directly address these medical costs of illness for
the family. The aforementioned case studies describe the positive benefits of
palliative care for the patient, and more quantitative studies have shown family
benefits [40]. One study found that hospice use is associated with a statisti-
cally significant decreased rate of death among surviving spouses [41]. (The
authors of the study suggest this is due to reduced stress.) Thus, it is important to
measure the benefits of palliative care in this domain.
These findings suggest the need for costing the health care use of key third
parties, such as caregivers, who are often family members. In addition, a QALY
analysis must be conducted for caregivers during the period of illness and,
ideally, up to 1 year after death, because this is the standard recommended length
of palliative care team support and interventions. Measuring the quality of life
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of caregivers raises questions similar to those that arise in attempting to measure
the quality of life of end-of-life patients. There are several instruments that
measure the quality-of-life of caregivers, often created for specific diseases [42].
In addition, a quality-of-life instrument for caregivers at the end-of-life is also in
development [43]. Whether these instruments should be adapted to an economic
analysis or whether it is sufficient to use existing health measurement scales for a
QALY analysis is a point that should be considered.
To see how a QALYanalysis would represent the benefits of palliative care for
the family, recall the aforementioned example where a patient in the last 6 months
of life increased her health-related quality of life from .30 to .40 on a scale from
0 (death) to 1 (full health), resulting in benefits of $2500. Suppose that palliative
care resulted in a ‘‘good death’’ that provided less stress and fewer physical and
mental health problems for a spouse caregiver. Assume this increased health
state is represented by a modest increase in health utility of .02 for the caregiver,
from .78 to .80. Though this may seem like a small increase, one should also
consider that the health effect will most likely last longer, past the death of the
spouse. If the effect were to last for 1 year (6 months before the end-of-life of the
spouse plus 6 months after the death of the spouse), then again using the con-
servative estimate of $50,000 per QALY, palliative care would achieve benefits of
$1000 in addition to those accrued to the patient. Though this is a theoretical
example, it is easy to see how neglect of these third-party benefits would lead to
an undervaluing of palliative care.
Family nonmedical costs and benefits
There is evidence that when individuals are chronically or seriously ill, family
caregivers trade off time in other activities to devote more time to the affected
individual [44–46]. They may take on fewer responsibilities at work or leave the
labor force entirely [47–49]. Palliative care might substitute for family caregiver
time and enable family members to return to work. On the other hand, it may
facilitate home care for patients who might otherwise be institutionalized and, as
a result, a family member may withdraw from the labor force to remain at home
with the patient.
In either event, the value of the associated change in family productivity must
be considered. Although there are no known studies of the effects of pallia-
tive care on family productivity, some related studies suggest that it could be
large. For example, one study of informal care of frail elderly estimated the lost
wages associated with caregiving at nearly $10,000 per frailty episode [50]. A
study of home care for ventilator-assisted children found that 39% of family
members had lost income from work [51]. Though this time lost might be hard
to evaluate in dollars, palliative care may also affect the academic performance
of school children.
In most communities, and most nations, the cumulative economic effects of
palliative care can be approximated by adding up the individual effects. This is
because only a small minority of individuals are dying at any time and may
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potentially benefit from palliative care. Thus, there is no ‘‘community wide’’
effect of palliative care apart from the effects on individuals. In some com-
munities in developing nations, for example those most heavily affected by HIV,
a nontrivial percentage of the population may require palliative care. In these
situations, the effects of palliative must also account for its impact on the
community and nation as a whole.
It is well understood in economics that when one examines the output of an
economy, ‘‘the whole is greater than the sum of the parts.’’ That is, one cannot
approximate total economic output by taking the marginal contribution of one
worker and multiplying by the number of workers. In the same way, the ag-
gregate effects of palliative care in some communities may exceed the sum of the
individual effects described above. In countries with a heavy burden of HIV/
AIDS in which large portions of the workforce are taken out by the epidemic,
these superadditive effects may be profound. In Botswana, for instance, 38.8% of
the adult population is estimated to be living with HIV/AIDS, and in Zimbabwe
the figure is 33.7% [52]. The proportion of caregivers must be similarly large
in both countries, and the number of those who are living with HIV/AIDS
and providing informal care is also likely to be high. The costs and benefits of
palliative care in these situations are not established. It is also not known how
much the nonlinear economic impact of palliative care might be in these situa-
tions. The potentially profound economic impact makes a reliable cost-benefit
analysis an urgent matter.
Cost-benefit studies of palliative care: how to collect the measures
The current CBA literature on palliative care focuses exclusively on patient
medical costs, with mixed results. It seems that the effect of palliative care on
aggregate medical costs is small. This suggests that patient nonmedical costs and
benefits as well as costs and benefits for the family can be decisive factors in
cost-benefit analysis. A complete economic study must take these into account.
This necessarily entails collecting far more information than is typical.
Patient medical costs
Current studies of patient medical costs rely on data from Medicare. Medicare
Part A reports charges for all inpatient services and Part B reports ancillary
charges, including physician services. Charges are based on provider fee
schedules and represent what would be paid by a patient with generous in-
demnity insurance. For most patients, the actual payments to providers are
determined by either government fiat (Medicare and Medicaid) or through
negotiations between payers and providers (managed care insurers). It is
notoriously difficult to obtain actual reimbursement data. Actual costs are also
difficult to estimate. Many researchers apply cost-to-charge ratios (obtained from
Medicare cost reports) to actual charges. This is an approximation at best because
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of the vagaries of overhead allocation. In recent years, many hospitals have
implemented activity-based cost accounting (ABC) systems that improve (but do
not perfect) overhead allocation. ABC hospitals may be able to provide
reasonably accurate cost estimates, even if their Medicare cost reports remain
problematic. Other providers, including physicians and extended care facilities,
do a much poorer job of allocating fixed costs. However, they also have fewer
fixed costs to allocate. The extent of errors in cost measurement among non-
hospital providers is unknown.
Patient medical benefits
The end of life is a sufficiently distinct life stage with its own health-related
domains that it is necessary to either supplement existing quality-of-life scales
developed for economic analysis or adapt existing psychometric scales of quality
of life at the end-of-life. Current health measurement scales will not suffice.
Dowie [53] suggests the use of a generic health measure instead of a condition-
specific measure whenever possible. It is unclear if using a generic measure with
added end-of-life domains would be a practical approach. Although it is essential
that such domains to be included when measuring quality-of-life at the end-of-life,
they may not be suited to evaluating health conditions in other life stages. Thus,
the end-of-life may be a situation unique enough to warrant the use of a condition-
specific measure and may fit with Dowie’s strict criteria for using a condition-
specific measure instead of a generic measure. The drawback to this approach is
that it may not be valid to compare end-of-life interventions with other inter-
ventions because using different sets of scales will yield different sets of health
utilities for health states across the life course. Comparisons between various
types of palliative care and usual hospital care can, however, still be performed.
Over the past 30 years several instruments have been proposed to measure
quality of care at the end of life or quality of death and dying [54,55]. A new
generation of instruments that incorporate the domains that are unique to the
end of life is being created to measure quality of life at the end of life [56,57].
However, these instruments have their roots in psychometrics rather than eco-
nomic theory. They were not designed to elicit health utilities but rather to
measure human characteristics. Thus, it will be necessary to take one of two
paths. New measures that are more in line with economic theory can be devised,
or health utilities can be extracted from current psychometric scales. Researchers
have used various statistical techniques to extract health utilities from the visual
analog scales (VAS) used in the SF-36 general health measure with some success
[58–60]. Even though the health utilities of the EQ-5D and SF-36 purport to
measure the same thing, in a population of liver transplant patients, they were
found to be more sensitive to lower and higher health states respectively [61].
Although they may be one way to obtain the health utilities necessary for a
QALYanalysis in the future,methods for extracting health utilities fromVAS instru-
ments cannot currently be used with confidence [62]. Constructing new quality-
of-life scales consistent with economic theory may be the more fruitful path.
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The health preferences of a community sample should be used to elicit health
utilities and to guide social policy decisions rather than individual treatment
decisions. However, once a certain amount of resources has been allocated to a
population subgroup, there is a strong argument for using the preferences of that
subgroup to determine which interventions should be funded and at what levels.
Daniels [63] makes a similar case with respect to Medicaid recipients. There are,
however, many practical barriers to obtaining preferences from palliative care
patients. Nonresponse bias due to the severity of illness ensures that a palliative
care population will be representative of only the least ill patients. The use of
caregiver proxies is a potential solution to this problem because there appears to
be a degree of agreement between patients and their caregiver proxies on health-
related quality-of-life questions [64]. Nonresponse due to the threatening nature
of standard gamble (SG) and time trade-off (TTO) questions may also bias
results, although the use of a chained SG and TTO method could somewhat
alleviate these problems [65]. Instead of using a patient population, the authors
suggest the modification of the methods of eliciting preferences from the general
population to make salient the issues unique to the end of life.
The two issues of importance in eliciting health preferences are time and
perspective. Palliative care patients who are, by definition, hospice eligible have a
prognosis of only 6 months or less. The TTO and SG methods assume that all
conditions are chronic until death. Death is, however, usually a distant con-
sideration or is used as part of a gamble to elicit preferences. To incorporate death
as an imminent consideration, the researcher should state this contextual fact
before the description of the health state domains and their severities. The
researcher should also insert it directly into the TTO or SG by making the health
state that is to be evaluated last only a few months instead of ‘‘for the rest of your
life’’ or a large number of years, as they are usually structured to do. The wording
of the question can also have an effect on the perspective frame used by the
respondent, be it personal, social, or socially inclusive personal [66]. Because
most people will experience a terminal state for a nontrivial amount of time, the
third perspective should be incorporated into the question as well.
Temporary health states within those last months of life can also be important
because terminal illness can progress through multiple varied stages, and the
temporary side effects of treatments can vary as well. For this reason, the
researcher should use a chained TTO or SG as described by Torrance [67] that
compares health states to an anchor state that must be carefully selected. The
chained TTO in particular has been shown to be particularly sensitive to small
changes in health states [68].
Patient nonmedical costs and benefits
Methods for collecting data associated with many relevant patient and family
nonmedical costs are well established. The approach used by Aday et al [51] in
their study of ventilator-dependent children is instructive. Children in this study
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were discharged from hospitals to receive care in their homes, and family
members were trained to assist skilled home nurses in providing care. Through
semistructured interviews with the parents of the affected children, researchers
documented a wide range of costs and benefits of hospital and home care.
Researchers began the interviews with open-ended questions, such as ‘‘Now that
[name of child] is home, what are your and your family’s greatest problems and
concerns?’’ Once they had identified a range of issues, interviewers asked for
details about specific areas of nonmedical costs, including ‘‘Did the family
member stop work at any time due to the child’s illness? Did the family member
spend time and money for transportation related to care for the child? Was there
lost vacation time? Were there any disruptions of education of family members?’’
All questions pertained to the period of time when the child was hospitalized and
the time when the child was home, reflecting the fact that these disruptions can
occur in either setting.
The Aday et al study [51] also considered family medical costs. Interviewers
inquired about family medical costs associated with mental health issues, such as
stress, feelings of abandonment, and loss of privacy. The researchers did not,
however, apply mental health QALY scores to their findings.
Family medical costs and benefits
To take into account the health effects on the informal caregiver or family
members, a certain number of third parties (if they exist) must be the target of a
separate costing and QALY analysis. While the situations of end-of-life
caregivers are distinct from the general population, they are unlikely to adopt
whole new domains of health-related quality of life. Their health risks are well
covered by the more mainstream physical, emotional, and social domains of
existing quality-of-life instruments. Thus, the researcher should use these instead
of a more condition-specific measure. The authors propose the inclusion of only
the primary caregiver or spouse in the analysis initially. The health effects beyond
the spouse or primary caregiver have not been adequately demonstrated.
However, future studies on health effects may warrant the extension of economic
analysis of family medical costs and benefits to other parties, such as non–
caregiving adult children. Analyses should extend to 1 year after the death of the
patient because that is benchmark for bereavement and the theoretical length of
palliative care interventions.
Measuring societal costs above and beyond the costs to individuals requires
measures of aggregate economic output at the community level. Obtaining such
measures in developing nations is unusual but not unprecedented [69].
Family nonmedical costs and benefits
Previous work that studied the impact of parental frailty (described above) has
typically made use of secondary data sources, such as the Health and Retirement
Study and the Study of Assets and Health Dynamics among the Oldest Old, or
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similar national surveys. These large national surveys provide a useful guide to
what palliative care researchers need to be mindful of in crafting future surveys
that will better address palliative care costs and benefits. It is important to elicit
information on assistance (all types, including time and financial) as well as
information work status for all adult children.
The largest nonmedical factor that is affected by a dying loved one, and thus
potentially impacted by palliative care, is work hours. In surveying family
members, longitudinal measures are preferred to cross-sectional measures, but are
often much more difficult and costly to acquire. A survey should first ascertain
whether each child is currently working for pay and the number of hours they
typically work per week. Because other factors beyond the health status of their
loved one will likely affect hours of work, it is important to get information on
wages, educational attainment, marital status and work status of spouse, number
and ages of their own children, age, and their own health status. With this in-
formation it is possible to construct a basic multivariate model to measure the
impact of palliative care on hours of work by family members and still control for
other confounding factors.
Summary
The previous literature evaluating the economic impact of palliative care has
reached a threshold. In particular, the focus on patient medical costs alone has
indicated that the advantages of palliative care are, at best, marginal. The effects
of palliative care on the family and on nonmedical costs may be significant but
have thus far been ignored, despite the fact that a central claim of the palliative
care movement is that the family is an important unit of concern. Palliative care
for elders may have some unique effects during the impending demographic
bulge, and studies on the economics of palliative care for elders are needed. Thus,
it is essential that future research measure the other economic components.
The authors have identified many components of palliative care that require
attention. The methods for collecting much of this information, including
nonmedical costs, are well established and merely need application to palliative
care. Methods for measuring quality-of-life for end-of-life patients are still being
developed. All future studies should include nonmedical costs and, eventually,
should add quantified measures of medical benefits. The magnitudes of these
effects may be great enough to profoundly change the way the cost/benefit ratio
of palliative care is perceived.
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